Latest Nicosan Stories

SAN DIEGO, Dec. 11, 2011 /PRNewswire-USNewswire/ -- Research assessing the safety and efficacy of hydroxyurea therapy in pediatric patients with sickle cell disease (SCD) and the use of pre-operative transfusions for patients with SCD who undergo low- and moderate-risk elective surgery will be presented today at the 53rd Annual Meeting of the American Society of Hematology. An estimated 90,000 to 100,000 Americans are affected each year by SCD, a serious disorder that causes normal...

Xechem International, Inc. (OTC BB: XKEM), Dr. Ramesh C. Pandey, the Chairman and CEO of Xechem International, will present at the 10th Annual New York Society of Security Analysts Biotech/Specialty Pharma Industry Conference in New York City on Tuesday, December 12th, 2006. He is scheduled to speak at 3:10 pm (EST). Dr. Pandey's presentation will cover the significant progress in Nigeria for production and distribution of Xechem's recently approved Sickle Cell drug NICOSAN™. In...